Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT J BUYNAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1508977984
CMS profile
340544
Location
VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,804.68

27 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,807.28 10
Food and Beverage $997.40 17

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,924.95 17
AstraZeneca Pharmaceuticals LP $729.73 8
Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 2

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT J BUYNAK

NPI 1508977984 · CMS profile ID 340544

Allopathic & Osteopathic Physicians / Internal Medicine

VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

27 matching records · $2,804.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 27 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–27 of 27.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $240.0009/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558606 CMS
ModernaTX, Inc. $318.9609/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558608 CMS
ModernaTX, Inc. $177.0109/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558610 CMS
ModernaTX, Inc. $265.5309/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558612 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558614 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558616 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558618 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558620 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558622 CMS
AstraZeneca Pharmaceuticals LP $24.4409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104288350 CMS
AstraZeneca Pharmaceuticals LP $27.9409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104385089 CMS
AstraZeneca Pharmaceuticals LP $27.9409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104473474 CMS
AstraZeneca Pharmaceuticals LP $81.0009/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104543482 CMS
AstraZeneca Pharmaceuticals LP $97.7809/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105367592 CMS
AstraZeneca Pharmaceuticals LP $71.2409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105375956 CMS
AstraZeneca Pharmaceuticals LP $292.3309/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105442631 CMS
AstraZeneca Pharmaceuticals LP $107.0609/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105540731 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $35.0001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118039628 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $115.0001/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118039630 CMS
ModernaTX, Inc. $150.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558536 CMS
ModernaTX, Inc. $217.3501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558538 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558540 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558542 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558544 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558600 CMS
ModernaTX, Inc. $50.0501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558602 CMS
ModernaTX, Inc. $50.0501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558604 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,627.38 35
PY2022 $1,515.77 9
PY2023 $2,547.31 21
PY2024 $2,804.68 27
PY2025 $2,542.53 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,038,550.53 603
PY2024 Principal investigator $5,031,915.33 601
PY2023 Recipient $906.71 2
PY2023 Principal investigator $4,138,599.32 2,384
PY2022 Recipient $3,104.59 10
PY2022 Principal investigator $5,204,363.35 1,133
PY2021 Principal investigator $3,348,948.64 610
PY2020 Recipient $1,489.26 13
PY2020 Principal investigator $1,938,354.41 292
PY2019 Recipient $658.79 10
PY2019 Principal investigator $1,439,149.33 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

2,386 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,133.80 12/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 991127119
Principal investigator 1 AstraZeneca Pharmaceuticals LP $777.75 12/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 991132953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067117
Principal investigator 1 ModernaTX, Inc. $33,545.77 12/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040222063
Principal investigator 1 GlaxoSmithKline, LLC. $11,000.00 12/20/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I No dispute reported 06/30/2026 1127786237
Principal investigator 1 ModernaTX, Inc. $7,939.85 12/20/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040222213
Principal investigator 1 ModernaTX, Inc. $58,745.00 12/20/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040222653
Principal investigator 1 Novo Nordisk AS $1,738.08 12/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007982959
Principal investigator 1 ModernaTX, Inc. $7,519.50 12/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1040220769
Principal investigator 1 ModernaTX, Inc. $3,638.80 12/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1040220821
Principal investigator 1 ModernaTX, Inc. $142,917.38 12/13/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040220757
Principal investigator 1 Mylan Specialty L.P. $8,005.80 12/13/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038210349
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343463
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343485
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343499
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343513
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343529
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343543
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343557
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343573
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343587
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343603
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343621
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343635
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343651
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343665
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343679
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343693
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343707
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343723
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343739
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343757
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343771
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343787
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343803
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343815
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343833
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343845
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343863
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343875
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343891
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343907
Principal investigator 1 Seqirus USA Inc $2,703.03 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343921
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343933
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343947
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343961
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343977
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021343991
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021344005
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021344023
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021344037
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021344053
Principal investigator 1 Seqirus USA Inc $2,703.04 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021344067
Principal investigator 1 ModernaTX, Inc. $69,817.35 12/08/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040221431
Principal investigator 1 ModernaTX, Inc. $65,498.45 12/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1040220883
Principal investigator 1 ModernaTX, Inc. $135.10 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040010717
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011775
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011781
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012969
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012975
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012981
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012987
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012993
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012999
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013005
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013011
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013019
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013025
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013029
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013037
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014713
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014719
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014725
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015347
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015351
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015358
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015363
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015369
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015376
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015383
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015389
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016025
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016031
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016037
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016043
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016049
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016055
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016061
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016067
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016073
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016079
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016083
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016089
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040016095
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017417
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017423
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017429
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018453
Principal investigator 1 ModernaTX, Inc. $76.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018459
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018465
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018471
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018477
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018483
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018489
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018495
Principal investigator 1 ModernaTX, Inc. $135.10 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018501
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018507
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018513
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018519
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018525
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018531
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018537
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018543
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018549
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018553
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018559
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021373
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021385
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023223
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023233
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023243
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023253
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023263
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023271
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023281
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023291
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023301
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023311
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023321
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023331
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023341
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023353
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023363
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023373
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023387
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023397
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023407
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023417
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023427
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023437
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023447
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040023457
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026197
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026207
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026217
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026227
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026237
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026251
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026261
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040026271
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028099
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028109
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028119
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028129
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028139
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028149
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028159
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028169
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029195
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029205
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029215
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029225
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029235
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029245
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029255
Principal investigator 1 ModernaTX, Inc. $281.61 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029265
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029273
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029283
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029293
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029301
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029311
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029323
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029333
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029343
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029351
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033813
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033821
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033831
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033841
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033851
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033861
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033871
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033881
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033891
Principal investigator 1 ModernaTX, Inc. $234.22 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033899
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033911
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033921
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033931
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033941
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033951
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033961
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033971
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033981
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033991
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034001
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034011
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034021
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034031
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036787
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036801
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036811
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036821
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036831
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038447
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038457
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038469
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038479
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038489
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038499
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038509
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038519
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038529
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038539
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038549
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038559
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038566
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038575
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038585
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038595
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040038605
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039711
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039721
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040041265
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040041275
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040041285
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043275
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043285
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043295
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043307
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043315
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043327
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043337
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043347
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043357
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043367
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043377
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040043389
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044533
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044543
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044555
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044565
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040045827
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040045837
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040045848
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040045859
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040045869
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048161
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048173
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048183
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048193
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048205
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048215
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048225
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048237
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048247
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048257
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048267
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049357
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049367
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049377
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049387
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049397
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049407
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049417
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049431
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049441
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049450
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049459
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051763
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051773
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051783
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051793
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051803
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051813
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051823
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051835
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040053521
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054601
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054610
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054621
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054631
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054641
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054653
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054663
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054673
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054683
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054693
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054703
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054715
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054727
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054737
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054747
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054759
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054769
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054779
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054789
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054799
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054809
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054819
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056735
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056741
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056749
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056757
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056765
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058537
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058545
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058551
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058561
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058569
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058577
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058585
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058593
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058601
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058609
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058617
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058625
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058633
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058641
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058649
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058657
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058665
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058673
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058681
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058689
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058697
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058705
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058713
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040058721
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061059
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061065
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061077
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061089
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063033
Principal investigator 1 ModernaTX, Inc. $281.61 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063043
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063053
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063065
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063073
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063083
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063093
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063103
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063113
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063123
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063133
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063143
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063153
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063163
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063173
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063185
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063195
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040064279
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040064289
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040064299
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040064309
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040065895
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040065905
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040067025
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040067033
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068211
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068221
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068231
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068242
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068251
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068261
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068271
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068281
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068291
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068301
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068311
Principal investigator 1 ModernaTX, Inc. $76.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068321
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068331
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068343
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068353
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068363
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068373
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068383
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068393
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071683
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071693
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071703
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071713
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073681
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073691
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073701
Principal investigator 1 ModernaTX, Inc. $76.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073711
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073721
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073731
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073741
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073751
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073761
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073771
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073781
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073791
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073801
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073811
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073821
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073831
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073841
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073851
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073861
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073871
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073881
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073891
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040073897
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076543
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076555
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076565
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076575
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076585
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078601
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078611
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078621
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078633
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078643
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078652
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078663
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078673
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078685
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078693
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078703
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078713
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078723
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078733
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078741
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078753
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078763
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081439
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081449
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081459
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081469
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081479
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083751
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083761
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083771
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083783
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083793
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083803
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083813
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083821
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083833
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083843
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083853
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083863
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083873
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083881
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083891
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083903
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086339
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086349
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086359
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086369
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086379
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086389
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088089
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088099
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088109
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088119
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088129
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088139
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088147
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088157
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089143
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089153
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089163
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089173
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089183
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089191
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089203
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089213
Principal investigator 1 ModernaTX, Inc. $76.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089219
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089227
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089237
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089243
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089253
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089263
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089273
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089283
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089289
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089299
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089309
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089317
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089327
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040089337
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093053
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093063
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093073
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093081
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093091
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093101
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093111
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094199
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094207
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094217
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094227
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094236
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094245
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094255
Principal investigator 1 ModernaTX, Inc. $135.10 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094263
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094273
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094283
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094293
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094303
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094315
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094325
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040094335
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096869
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096877
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096887
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096897
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096907
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096917
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098021
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098033
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098043
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098053
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098063
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098073
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098083
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098093
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098103
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098113
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098123
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098133
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098143
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098153
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098163
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098173
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098183
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098193
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100989
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100999
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101009
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101019
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103309
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103319
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103331
Principal investigator 1 ModernaTX, Inc. $234.22 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103341
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103351
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103361
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103371
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103381
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103391
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103401
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103411
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103421
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103433
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103443
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103455
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103465
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103475
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103485
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040103495
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107243
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107254
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107265
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107281
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109671
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109683
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109695
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109707
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109719
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109731
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109743
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109755
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109767
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109781
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109793
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109805
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109817
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109829
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109847
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109859
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109871
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109882
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109897
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109909
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109921
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109933
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109947
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109961
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109973
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109985
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109997
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110011
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112747
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112759
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112771
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112783
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112795
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112807
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040112817
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115093
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115105
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115117
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115129
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115141
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115153
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115165
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115177
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115190
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115201
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115213
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115225
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115237
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115249
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116603
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116615
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116629
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116641
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116653
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119621
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119633
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119645
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119657
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119669
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122181
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122193
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122205
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122217
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122229
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122241
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122253
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122266
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122281
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122293
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122305
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122317
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122329
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122341
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122353
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122365
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122377
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122391
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122403
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122417
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122427
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122443
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040122453
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125323
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125335
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125347
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128727
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128739
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128751
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128763
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128775
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128789
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128801
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128813
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128825
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128837
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128851
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128863
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128877
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128889
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128901
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128913
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128927
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128939
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128951
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128963
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040132135
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134107
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134119
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134129
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134143
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134155
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134167
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134181
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134193
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134205
Principal investigator 1 ModernaTX, Inc. $135.10 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134217
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134229
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134243
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134255
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134267
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134279
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134291
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134301
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134313
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134325
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134337
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134349
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134361
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040138115
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040138127
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040138141
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140751
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140763
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140775
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140787
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140799
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140817
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140829
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140841
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140853
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140865
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140877
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140889
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140901
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140913
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140923
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140933
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140945
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140963
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040140975
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142235
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142249
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142259
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142275
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142287
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142299
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142311
Principal investigator 1 ModernaTX, Inc. $234.22 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040142323
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040144280
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040144297
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040144307
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040144319
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146721
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146733
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146745
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146755
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146769
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146783
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146795
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146807
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146819
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146831
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146845
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146857
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146869
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146881
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146893
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040146905
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040148273
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040148285
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040150125
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040150137
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151511
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153861
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153871
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153885
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153897
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153909
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153921
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153933
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153945
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153957
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153969
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153981
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153993
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154005
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154017
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154029
Principal investigator 1 ModernaTX, Inc. $76.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154041
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154053
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154065
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154077
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154089
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154101
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154113
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154125
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154137
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154149
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154159
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040156347
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160241
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160255
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160267
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160279
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160293
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160305
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160317
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160329
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160341
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160353
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160365
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160377
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160391
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160401
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160413
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160425
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160437
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160449
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160461
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160473
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040160487
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163593
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163607
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165909
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165923
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165937
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165949
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165961
Principal investigator 1 ModernaTX, Inc. $281.61 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165973
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165985
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165997
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166009
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166021
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166033
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166047
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166059
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166069
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166081
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166095
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166107
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169465
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169477
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169492
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169505
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169517
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169529
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040170797
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172159
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172173
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172185
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172197
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172209
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172221
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172235
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172247
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172259
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172271
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172283
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172295
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172307
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172321
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172331
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172343
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172355
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040172367
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040175283
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040175297
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040175311
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040175325
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040175339
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040175355
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178687
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178701
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178715
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178731
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178743
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178757
Principal investigator 1 ModernaTX, Inc. $83.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178771
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178785
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178799
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178813
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178827
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178841
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178855
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178869
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178883
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178897
Principal investigator 1 ModernaTX, Inc. $419.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178911
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178925
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178939
Principal investigator 1 ModernaTX, Inc. $62.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178951
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178965
Principal investigator 1 ModernaTX, Inc. $1.40 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066587
Principal investigator 1 Novo Nordisk AS $23.06 11/29/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,263.00 11/27/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067563
Principal investigator 1 Novo Nordisk AS $4,656.60 11/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007982949
Principal investigator 1 ModernaTX, Inc. $85,730.80 11/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040220293
Principal investigator 1 Novo Nordisk AS $23.06 11/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997815
Recipient Novo Nordisk AS $371.70 11/12/2023 Covered Recipient Physician NN SELECT Results Meeting Philadelphia No dispute reported 06/30/2026 1061079591
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/03/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127785731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066392
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066483
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,500.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research Durham
phase III efficacy for obesity with T2DM No dispute reported 06/30/2026 1022139477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,500.00 10/31/2023 Non-covered Recipient Entity
Velocity Clinical Research Durham
Phase III efficacy for obesity without T2DM No dispute reported 06/30/2026 1022139705
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961287
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961293
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961299
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961305
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962111
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962117
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962223
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962227
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962233
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962239
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962245
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962487
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962493
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962499
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963109
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963115
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963121
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963399
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963815
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963821
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963827
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963833
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963839
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964257
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964262
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964679
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964685
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964691
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964697
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964975
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964981
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964987
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964993
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964999
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965261
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965269
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965275
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965281
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965287
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966215
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966221
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966559
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966567
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966945
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966953
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966958
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966963
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966971
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967331
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967337
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967343
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967525
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967531
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967537
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967543
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967549
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967555
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967949
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968307
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968313
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968319
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968325
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968547
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968553
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968759
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968765
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969397
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969711
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970311
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970317
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970371
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970379
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970385
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970815
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970821
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970827
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970833
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971367
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971373
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971715
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971721
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971727
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971733
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971941
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971947
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971953
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971959
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972395
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972401
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972405
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972411
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 10/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127786235
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127791948
Principal investigator 1 ModernaTX, Inc. $28,249.20 10/27/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040218585
Principal investigator 1 PFIZER INC. $27,000.00 10/27/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045869643
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039917735
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039919220
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921371
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921385
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921399
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039923547
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039923561
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039925565
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039925581
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039928869
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039928881
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039932239
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039935203
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039935213
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039936933
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039936945
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039938677
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039938687
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939827
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939837
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039941405
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944943
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944951
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944961
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944971
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944981
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945865
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945875
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945885
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039947303
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039949413
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950223
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952277
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952283
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952289
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953113
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953119
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953125
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954189
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955825
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955831
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955837
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957467
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957473
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957479
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957485
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958745
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958753
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959621
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959627
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959633
Principal investigator 1 Novo Nordisk AS $432.00 10/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007982937
Principal investigator 1 Novo Nordisk AS $5,019.48 10/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007982979
Principal investigator 1 Seqirus USA Inc $9,000.00 10/23/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021338943
Principal investigator 1 Seqirus USA Inc $2,000.00 10/23/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021338958
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,972.00 10/20/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067495
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,381.32 10/20/2023 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
phase III efficacy for obesity with T2DM No dispute reported 06/30/2026 1022135477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,721.32 10/16/2023 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
Phase III efficacy for obesity without T2DM No dispute reported 06/30/2026 1022137747
Principal investigator 1 PFIZER INC. $27,438.75 10/14/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046299807
Principal investigator 1 GlaxoSmithKline, LLC. $57,587.31 10/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127785723
Principal investigator 1 Eli Lilly and Company $19,153.00 10/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038153551
Principal investigator 1 ModernaTX, Inc. $71,528.40 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040218083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $93.00 10/04/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997067611
Principal investigator 1 Novo Nordisk AS $432.00 10/04/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007982969
Principal investigator 1 Boehringer Ingelheim International GmbH $4,456.26 10/01/2023 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
Phase III efficacy for obesity without T2DM No dispute reported 06/30/2026 1007644043
Principal investigator 1 Boehringer Ingelheim International GmbH $4,688.96 10/01/2023 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
phase III efficacy for obesity with T2DM No dispute reported 06/30/2026 1007646667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066289
Principal investigator 1 SANOFI PASTEUR INC. $38,926.18 09/29/2023 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035888143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,438.00 09/26/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997067395
Principal investigator 1 Novo Nordisk AS $350.00 09/25/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1007196047
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,750.00 09/23/2023 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C No dispute reported 06/30/2026 1017240069
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1040206697
Principal investigator 1 ModernaTX, Inc. $10,000.00 09/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1040216955
Principal investigator 1 ModernaTX, Inc. $4,046.29 09/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040216979
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1040223615
Principal investigator 1 Novo Nordisk AS $428.13 09/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1007196035
Principal investigator 1 Novo Nordisk AS $2,739.96 09/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997763
Principal investigator 1 Novo Nordisk AS $23.06 09/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997795
Principal investigator 1 Novo Nordisk AS $3,597.48 09/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $912.00 09/15/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066979
Principal investigator 1 ModernaTX, Inc. $86,830.00 09/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040217355
Recipient Eli Lilly and Company $535.01 09/13/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038056127
Principal investigator 1 Novavax Inc $1,239.00 09/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258843
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865169
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865193
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039875093
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039875107
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039879947
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039879963
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039882591
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039883593
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039883603
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 09/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127785719
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127785721
Principal investigator 1 GlaxoSmithKline, LLC. $9,000.00 09/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127791946
Principal investigator 1 Janssen Pharmaceuticals, Inc $13,675.00 09/06/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094923
Principal investigator 1 Janssen Pharmaceuticals, Inc $89.00 09/01/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094921
Principal investigator 1 ModernaTX, Inc. $2,593.35 09/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040216381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066271
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 08/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127785729
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 08/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127791944
Principal investigator 1 Eli Lilly and Company $1,254.55 08/28/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038155123
Principal investigator 1 PFIZER INC. $403.92 08/24/2023 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045894911
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 08/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127785727
Principal investigator 1 GlaxoSmithKline, LLC. $952.38 08/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127785733
Principal investigator 1 ModernaTX, Inc. $62,731.60 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040216113
Principal investigator 1 PFIZER INC. $850.50 08/22/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045983117
Principal investigator 1 ModernaTX, Inc. $1,250.44 08/18/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040215803
Principal investigator 1 Novo Nordisk AS $10,134.47 08/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1007196025
Principal investigator 1 Novo Nordisk AS $358.56 08/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007926985
Principal investigator 1 SANOFI PASTEUR INC. $2,655.00 08/18/2023 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035888057
Principal investigator 1 SANOFI PASTEUR INC. $2,673.00 08/18/2023 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035888067
Principal investigator 1 SANOFI PASTEUR INC. $396.00 08/18/2023 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035888213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/17/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/17/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065971
Principal investigator 1 PFIZER INC. $1,417.50 08/17/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046236649
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040203877
Principal investigator 1 ModernaTX, Inc. $82,844.80 08/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040214975
Principal investigator 1 Novo Nordisk AS $23.06 08/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997779
Principal investigator 1 Janssen Research & Development, LLC $1,340.00 08/11/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120331
Principal investigator 1 Novavax Inc $13,950.00 08/10/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263703
Principal investigator 1 ModernaTX, Inc. $2,917.69 08/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040214505
Principal investigator 1 ModernaTX, Inc. $1,300.00 08/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040214551
Principal investigator 1 PFIZER INC. $850.50 08/09/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046022365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,672.00 08/02/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066911
Principal investigator 1 ModernaTX, Inc. $14,875.00 08/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040203865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997066027
Principal investigator 1 Novo Nordisk AS $1,225.80 07/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007926979
Principal investigator 1 ModernaTX, Inc. $791.92 07/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040214327
Principal investigator 1 GlaxoSmithKline, LLC. $43,320.42 07/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127786241
Principal investigator 1 Novavax Inc $1,512.00 07/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258847
Principal investigator 1 Novo Nordisk AS $14,108.82 07/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070511
Principal investigator 1 Novo Nordisk AS $4,190.00 07/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070527
Principal investigator 1 Novo Nordisk AS $7,500.00 07/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070547
Principal investigator 1 Novo Nordisk AS $4,537.50 07/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070563
Principal investigator 1 PFIZER INC. $1,701.00 07/26/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046287699
Principal investigator 1 PFIZER INC. $313.88 07/25/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045863741
Principal investigator 1 Eli Lilly and Company $51,346.25 07/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM PHASE 4 STUDY TO ASSESS GLYCEMIC CONTROL WHEN ADULTS WITH TYPE 2 DIABETES SWITCH FROM A GLP-1 RA TO TIRZEPATIDE (SURPASS-SWITCH-2) No dispute reported 06/30/2026 1038150175
Principal investigator 1 Janssen Pharmaceuticals, Inc $11,911.00 07/21/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094927
Principal investigator 1 Novo Nordisk AS $23.06 07/21/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990261
Principal investigator 1 PFIZER INC. $850.50 07/19/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046163937
Principal investigator 1 Novavax Inc $2,419.00 07/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259811
Principal investigator 1 Novavax Inc $235.00 07/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $498.00 07/17/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997067009
Principal investigator 1 ModernaTX, Inc. $51,031.60 07/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040212655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,072.00 07/12/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,060.00 07/12/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066997
Principal investigator 1 Novavax Inc $1,277.00 07/11/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258845
Principal investigator 1 Janssen Pharmaceuticals, Inc $375.00 07/07/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094925
Principal investigator 1 Janssen Research & Development, LLC $14,850.00 07/07/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120323
Principal investigator 1 PFIZER INC. $1,569.40 07/06/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045867481
Principal investigator 1 GlaxoSmithKline, LLC. $1,415.70 07/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127785725
Principal investigator 1 Novavax Inc $1,747.00 07/04/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261793
Principal investigator 1 ModernaTX, Inc. $10,926.90 07/03/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040212095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065801
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990133
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990147
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990165
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990183
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990195
Principal investigator 1 Novo Nordisk AS $29.97 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990213
Principal investigator 1 Novo Nordisk AS $196.47 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990229
Principal investigator 1 Novo Nordisk AS $7.99 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007649801
Principal investigator 1 Novo Nordisk AS $14.98 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007649809
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007649821
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007649833
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007649845
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997609
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997627
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997643
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997659
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997675
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997697
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997713
Principal investigator 1 Novo Nordisk AS $5.41 06/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997729
Principal investigator 1 PFIZER INC. $567.00 06/29/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046331867
Principal investigator 1 ModernaTX, Inc. $91,270.40 06/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040212579
Principal investigator 1 Novavax Inc $235.00 06/28/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259809
Principal investigator 1 Novavax Inc $3,946.80 06/28/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262815
Principal investigator 1 PFIZER INC. $6,277.60 06/27/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045869601
Principal investigator 1 Novo Nordisk AS $23.06 06/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990245
Principal investigator 1 Novo Nordisk AS $717.12 06/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007926973
Principal investigator 1 Novo Nordisk AS $6,593.09 06/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070477
Principal investigator 1 Novo Nordisk AS $6,000.00 06/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070493
Principal investigator 1 Novavax Inc $235.00 06/20/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 06/18/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 06/18/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28.35 06/18/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065635
Principal investigator 1 ModernaTX, Inc. $14,254.56 06/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040211949
Principal investigator 1 ModernaTX, Inc. $1,187.88 06/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040211961
Principal investigator 1 ModernaTX, Inc. $1,278.00 06/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040212009
Principal investigator 1 PFIZER INC. $1,701.00 06/16/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045980201
Principal investigator 1 GlaxoSmithKline, LLC. $1,853.28 06/14/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127791942
Principal investigator 1 ModernaTX, Inc. $34,615.60 06/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040211497
Principal investigator 1 PFIZER INC. $9,072.00 06/14/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046033971
Principal investigator 1 Novavax Inc $9,456.00 06/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264721
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039813957
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039813965
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039813973
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039813981
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039813989
Principal investigator 1 ModernaTX, Inc. $1,855.52 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039813997
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814007
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814014
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814023
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814031
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814039
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814047
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814055
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814063
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814071
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814079
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814087
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814095
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814103
Principal investigator 1 ModernaTX, Inc. $1,855.52 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814111
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814119
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814127
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814135
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814143
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814151
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814159
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814167
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814175
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814183
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814191
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814199
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814207
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814215
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814223
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814231
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814239
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814247
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814255
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814263
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814271
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814279
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814287
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814295
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814303
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814313
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814319
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814327
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814337
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814345
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814351
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814361
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814367
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814375
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814383
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814391
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814399
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814407
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814415
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814423
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814431
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814439
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814447
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814455
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814463
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814471
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814479
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814487
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814495
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814503
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814511
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814519
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814528
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814535
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814543
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814551
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814561
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814567
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814575
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814583
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814591
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814599
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814607
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814617
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814625
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814633
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814641
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814649
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814657
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814661
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814669
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814677
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814685
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814693
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814701
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814709
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814717
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814725
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814733
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814741
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814749
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814757
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814765
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814773
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814781
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814789
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814799
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814807
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814813
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814821
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814829
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814837
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814845
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814853
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814861
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814869
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814877
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814885
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814893
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814901
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814909
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814917
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814925
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814931
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814939
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814947
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814955
Principal investigator 1 ModernaTX, Inc. $2,885.02 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814963
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814971
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814977
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814985
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039814993
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815001
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815009
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815018
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815029
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815033
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815043
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815049
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815059
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815067
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815075
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815085
Principal investigator 1 ModernaTX, Inc. $2,703.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815093
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815101
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815109
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815117
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815125
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815133
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815143
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815151
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815159
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815167
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815175
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815183
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815191
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815199
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815209
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815215
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815223
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815231
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815239
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815247
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815255
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815265
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815275
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815283
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815290
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815297
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815307
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815315
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815323
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815331
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815336
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815343
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815353
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815361
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815369
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815375
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815385
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815393
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815399
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815409
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815417
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815423
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815431
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815441
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815449
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815457
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815467
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815475
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815483
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815491
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815501
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815509
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815517
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815525
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815533
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815541
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815551
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815559
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815567
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815575
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815583
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815591
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815599
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815607
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815615
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815623
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815631
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815639
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815647
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815655
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815665
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815673
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815681
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815689
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815697
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815705
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815713
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815721
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815729
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815737
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815745
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815753
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815761
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815769
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815777
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815785
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815793
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815801
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815809
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815817
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815825
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815833
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815841
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815849
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815857
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815865
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815873
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815881
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815887
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815895
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815903
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815911
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815919
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815927
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815935
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815943
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815953
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815959
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815968
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815977
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815985
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039815993
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816001
Principal investigator 1 ModernaTX, Inc. $641.03 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816009
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816017
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816027
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816033
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816041
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816049
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816057
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039816065
Principal investigator 1 Janssen Research & Development, LLC $8,775.00 06/09/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120195
Principal investigator 1 Novavax Inc $1,982.00 06/08/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258841
Principal investigator 1 ModernaTX, Inc. $929.10 06/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039785633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 06/06/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 06/06/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065617
Principal investigator 1 PFIZER INC. $3,685.50 06/03/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046336685
Principal investigator 1 Janssen Research & Development, LLC $21,330.00 06/02/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065739
Principal investigator 1 ModernaTX, Inc. $132.80 05/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041563907
Principal investigator 1 Novo Nordisk AS $23.06 05/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997593
Principal investigator 1 Novavax Inc $1,175.00 05/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262811
Principal investigator 1 Novo Nordisk AS $1,149.12 05/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007939801
Principal investigator 1 Novo Nordisk AS $8,958.98 05/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070461
Principal investigator 1 PFIZER INC. $1,255.52 05/26/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045869615
Principal investigator 1 PFIZER INC. $567.00 05/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045928133
Principal investigator 1 Janssen Pharmaceuticals, Inc $170.00 05/24/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094771
Principal investigator 1 ModernaTX, Inc. $70,805.60 05/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040210971
Principal investigator 1 ModernaTX, Inc. $2,500.00 05/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040614315
Principal investigator 1 ModernaTX, Inc. $1,200.00 05/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040615247
Principal investigator 1 ModernaTX, Inc. $11,000.00 05/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040615659
Principal investigator 1 ModernaTX, Inc. $2,500.00 05/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040615677
Principal investigator 1 Novavax Inc $2,452.00 05/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263701
Principal investigator 1 Janssen Research & Development, LLC $12,936.00 05/22/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120175
Principal investigator 1 Janssen Research & Development, LLC $18,385.00 05/19/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120183
Principal investigator 1 Janssen Research & Development, LLC $36,327.00 05/17/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120155
Principal investigator 1 ModernaTX, Inc. $9,899.00 05/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040210773
Principal investigator 1 Novo Nordisk AS $23.06 05/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997575
Principal investigator 1 Novavax Inc $8,085.00 05/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265763
Principal investigator 1 Novo Nordisk AS $20.10 05/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070427
Principal investigator 1 ModernaTX, Inc. $1,920.00 05/10/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040202233
Principal investigator 1 PFIZER INC. $405.00 05/10/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046297779
Principal investigator 1 Novavax Inc $4,097.00 05/09/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259807
Principal investigator 1 Janssen Research & Development, LLC $20,047.00 05/05/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120179
Principal investigator 1 ModernaTX, Inc. $7,008.86 05/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040209679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,263.00 05/03/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066825
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,680.00 05/03/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094769
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533035
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533051
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533069
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533085
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533101
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533117
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533135
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533151
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533171
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533187
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533203
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533219
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040533235
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537977
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537993
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538009
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538027
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538043
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538059
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538075
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538091
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538107
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538121
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538137
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538153
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538169
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040538185
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542857
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542875
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542891
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542905
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542921
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542937
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542953
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542969
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542983
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542999
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040543017
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040543035
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040543051
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040543067
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548007
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548023
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548041
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548057
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548073
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548091
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548109
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548125
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548141
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548157
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548173
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548189
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548205
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548221
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548237
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548253
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040548271
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552771
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552785
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552801
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552817
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552834
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552849
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552865
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552883
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552899
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552915
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557617
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557633
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557649
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557665
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557685
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557701
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557717
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557732
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557747
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557765
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557781
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557799
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557815
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557831
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557849
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557867
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557883
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557899
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557915
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562635
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562651
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562669
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562685
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562701
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562717
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562735
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562751
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562767
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562783
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562799
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562815
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567913
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567929
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567945
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567963
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567979
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567997
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568013
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568029
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568048
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568063
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568079
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568095
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568111
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040568129
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573264
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573281
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573297
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573315
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573331
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573349
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573363
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573381
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573399
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578605
Principal investigator 1 ModernaTX, Inc. $566.02 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578623
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578639
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578655
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578671
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578687
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578703
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578719
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578737
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578753
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578771
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583695
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583711
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583727
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583743
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583757
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583773
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583787
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583803
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583819
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583839
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583853
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583871
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583887
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583903
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583919
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583935
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583951
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583967
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583983
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583999
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589181
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589202
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589217
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589233
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589251
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589267
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589283
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589297
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589313
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589330
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589347
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589363
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589375
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589391
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589411
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589427
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589443
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040589459
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594307
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594321
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594337
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594351
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594369
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594385
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594401
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594417
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599211
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599231
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599247
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599263
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599279
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599295
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599311
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599325
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599341
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599357
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599373
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599389
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599405
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040599421
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604101
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604117
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604135
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604149
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604168
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604185
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604201
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604217
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604233
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040604249
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608795
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608809
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608827
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608843
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608857
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608873
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608889
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608907
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997065703
Principal investigator 1 ModernaTX, Inc. $33,635.60 04/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040210381
Principal investigator 1 Novavax Inc $3,564.00 04/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265757
Principal investigator 1 Novavax Inc $4,700.00 04/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265759
Principal investigator 1 Novo Nordisk AS $1,075.68 04/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1007939791
Principal investigator 1 Novo Nordisk AS $4,021.90 04/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070443
Principal investigator 1 Janssen Research & Development, LLC $13,510.00 04/21/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120191
Principal investigator 1 PFIZER INC. $202.50 04/21/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046295185
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,914.00 04/19/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094773
Principal investigator 1 ModernaTX, Inc. $79,569.20 04/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040210367
Principal investigator 1 ModernaTX, Inc. $33.30 04/19/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041563839
Principal investigator 1 Novavax Inc $2,585.00 04/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258839
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,441.27 04/14/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 991140175
Principal investigator 1 Novavax Inc $2,350.00 04/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259805
Principal investigator 1 GlaxoSmithKline, LLC. $6,559.74 04/07/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786239
Principal investigator 1 PFIZER INC. $607.50 04/05/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046021745
Principal investigator 1 Novavax Inc $2,115.00 04/04/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065142
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065259
Principal investigator 1 Novavax Inc $2,585.00 03/29/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,175.00 03/28/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066673
Principal investigator 1 ModernaTX, Inc. $99,858.80 03/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040209253
Principal investigator 1 Novavax Inc $1,282.00 03/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055261791
Principal investigator 1 Novavax Inc $470.00 03/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264723
Principal investigator 1 Novo Nordisk AS $23.06 03/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1006990279
Principal investigator 1 Novo Nordisk AS $432.00 03/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997507
Principal investigator 1 Novo Nordisk AS $3,107.27 03/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1009070411
Principal investigator 1 Janssen Pharmaceuticals, Inc $17,487.00 03/22/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094645
Principal investigator 1 Novavax Inc $2,350.00 03/21/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260803
Principal investigator 1 SANOFI PASTEUR INC. $164,385.74 03/21/2023 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035887853
Principal investigator 1 Janssen Research & Development, LLC $804.00 03/20/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,649.00 03/17/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066667
Principal investigator 1 ModernaTX, Inc. $166.50 03/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - VALPARAISO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041563545
Principal investigator 1 Novavax Inc $8,364.00 03/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262809
Principal investigator 1 Novavax Inc $2,820.00 03/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 03/14/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 03/14/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 03/14/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065279
Principal investigator 1 PFIZER INC. $2,430.00 03/09/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045920901
Principal investigator 1 Novavax Inc $8,352.00 03/08/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258837
Principal investigator 1 Novavax Inc $1,880.00 03/08/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,654.00 03/01/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066661
Principal investigator 1 ModernaTX, Inc. $4,572.11 03/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040208505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065074
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065123
Principal investigator 1 Novavax Inc $6,707.00 02/28/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259803
Principal investigator 1 Novavax Inc $470.00 02/28/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263697
Principal investigator 1 PFIZER INC. $11,947.50 02/28/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045985827
Principal investigator 1 ModernaTX, Inc. $17,243.21 02/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040208491
Principal investigator 1 Janssen Pharmaceuticals, Inc $18,010.00 02/23/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,594.64 02/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 991140971
Principal investigator 1 Novavax Inc $6,267.00 02/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259801
Principal investigator 1 Novavax Inc $33,671.00 02/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262807
Principal investigator 1 Novo Nordisk AS $4,642.90 02/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1007480145
Principal investigator 1 Novo Nordisk AS $2,086.56 02/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997539
Principal investigator 1 PFIZER INC. $5,953.50 02/18/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046291873
Principal investigator 1 GlaxoSmithKline, LLC. $10,878.12 02/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1006176067
Principal investigator 1 ModernaTX, Inc. $79,836.40 02/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040208255
Principal investigator 1 Novavax Inc $2,585.00 02/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260801
Principal investigator 1 Novavax Inc $34,933.00 02/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263699
Principal investigator 1 Janssen Research & Development, LLC $2,814.00 02/15/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120007
Principal investigator 1 Novo Nordisk AS $23.06 02/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997557
Principal investigator 1 ModernaTX, Inc. $50,449.60 02/10/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040208229
Principal investigator 1 PFIZER INC. $23,814.00 02/10/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046021775
Principal investigator 1 Novavax Inc $44,390.00 02/09/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260797
Principal investigator 1 Novavax Inc $2,585.00 02/09/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260799
Principal investigator 1 Janssen Research & Development, LLC $92,898.00 02/08/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120011
Principal investigator 1 PFIZER INC. $11,907.00 02/07/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046021761
Principal investigator 1 Novavax Inc $4,152.00 02/02/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265753
Principal investigator 1 Janssen Research & Development, LLC $70,185.00 02/01/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120015
Principal investigator 1 ModernaTX, Inc. $67,508.40 02/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040208129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997064513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997064995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2023 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997065007
Principal investigator 1 Novo Nordisk AS $59.94 01/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997491
Principal investigator 1 ModernaTX, Inc. $23,200.42 01/27/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040207197
Principal investigator 1 GlaxoSmithKline, LLC. $11,076.12 01/25/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1006176077
Principal investigator 1 Janssen Pharmaceuticals, Inc $10,337.00 01/25/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094649
Principal investigator 1 Janssen Research & Development, LLC $198,964.00 01/25/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120019
Principal investigator 1 Novavax Inc $2,115.00 01/25/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261789
Principal investigator 1 Novo Nordisk AS $5,724.58 01/25/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1007480135
Principal investigator 1 Novo Nordisk AS $1,510.92 01/25/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997523
Principal investigator 1 Novo Nordisk AS $11.64 01/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 1007480123
Principal investigator 1 ModernaTX, Inc. $14,864.17 01/20/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040206057
Principal investigator 1 Novavax Inc $5,963.00 01/20/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263695
Principal investigator 1 Novo Nordisk AS $23.06 01/20/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 1008997475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,225.00 01/13/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066655
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406799
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406815
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406831
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406845
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406861
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406877
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406891
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406911
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406927
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406941
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406957
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406971
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410641
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410653
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410669
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410683
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410699
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410713
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410727
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410743
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410759
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410773
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410793
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414003
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414021
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414037
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414051
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414067
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414083
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414099
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040414113
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417559
Principal investigator 1 ModernaTX, Inc. $2,534.49 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417575
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417591
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417605
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417621
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417635
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417651
Principal investigator 1 ModernaTX, Inc. $684.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417667
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420711
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420721
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420737
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420749
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420759
Principal investigator 1 ModernaTX, Inc. $684.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420769
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423801
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423813
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423825
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423837
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423849
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423861
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423871
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423883
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423897
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423909
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423921
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423933
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423945
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423957
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423969
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426851
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426863
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426875
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426887
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426903
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426915
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426927
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426939
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426951
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426963
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426975
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426987
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426999
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040427011
Principal investigator 1 ModernaTX, Inc. $1,215.90 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040427023
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040427035
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040427047
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429697
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429707
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429721
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429733
Principal investigator 1 ModernaTX, Inc. $1,215.90 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429745
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429755
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432485
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432497
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432509
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432519
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432529
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432543
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432555
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432569
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432581
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432591
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432605
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432617
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432629
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432639
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435281
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435293
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435305
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435317
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435329
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435341
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435353
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435365
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438349
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438361
Principal investigator 1 ModernaTX, Inc. $1,215.90 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438371
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438379
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438387
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438395
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438403
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438411
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438419
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438429
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438436
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438447
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438459
Principal investigator 1 ModernaTX, Inc. $1,215.90 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438471
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441129
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441141
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441153
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441165
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441177
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441189
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441201
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441215
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441227
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441241
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444235
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444247
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444259
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444271
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444283
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444295
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444307
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444319
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444331
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444343
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448237
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448253
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448273
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448287
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448303
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451863
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451877
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451891
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451911
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451927
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451939
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451953
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451965
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451979
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451995
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040452011
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455545
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455561
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455583
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455601
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455617
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455631
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455649
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455665
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455679
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455695
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455713
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455729
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455745
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455763
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459581
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459597
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459615
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459631
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459647
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459663
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459679
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459695
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459711
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459727
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459745
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459759
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459775
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459795
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459811
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463659
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463675
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463691
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463707
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463723
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463737
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463755
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463773
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463789
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463805
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463817
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467355
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467369
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467387
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467403
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467423
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467439
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467455
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471427
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471441
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471457
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471475
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471491
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471509
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471525
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471545
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471561
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471577
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471593
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471609
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475611
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475627
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475643
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475665
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475681
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475697
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475713
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475729
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475745
Principal investigator 1 ModernaTX, Inc. $684.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475761
Principal investigator 1 ModernaTX, Inc. $684.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475777
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479401
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479419
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479435
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479451
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479467
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479485
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479501
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479517
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483621
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483637
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483653
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483669
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483685
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483701
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483717
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483733
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040487006
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040487025
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040487041
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040487057
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040487071
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040487089
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490785
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490801
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490817
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490833
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490849
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490865
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490881
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490895
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490913
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490929
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490945
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490961
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490977
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494317
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494335
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494351
Principal investigator 1 ModernaTX, Inc. $684.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494365
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494381
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494401
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494417
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494433
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494449
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494465
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494481
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494497
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498235
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498251
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498267
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498283
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498299
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498317
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501839
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501855
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501871
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501889
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501909
Principal investigator 1 ModernaTX, Inc. $2,107.98 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501923
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501937
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501953
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501969
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505701
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505719
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505737
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505753
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505771
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505787
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505805
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505821
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505837
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505853
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505869
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509549
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509565
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509577
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509592
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513291
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513305
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513319
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513337
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513353
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513367
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513383
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513400
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517639
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517653
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517665
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517681
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517697
Principal investigator 1 ModernaTX, Inc. $558.18 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517719
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517739
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517755
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517769
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517785
Principal investigator 1 ModernaTX, Inc. $753.48 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517799
Principal investigator 1 ModernaTX, Inc. $3,779.37 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517815
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517831
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517847
Principal investigator 1 ModernaTX, Inc. $1,215.90 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517863
Principal investigator 1 ModernaTX, Inc. $12.60 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517881
Principal investigator 1 PFIZER INC. $3,969.00 01/12/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046099197
Principal investigator 1 PFIZER INC. $3,969.00 01/11/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046087943
Principal investigator 1 Novavax Inc $1,348.00 01/10/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259799
Principal investigator 1 Novavax Inc $2,115.00 01/10/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263693
Principal investigator 1 Novavax Inc $14,164.00 01/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260795
Principal investigator 1 Novavax Inc $4,502.00 01/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,680.00 01/04/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997066649